Large cohort studies and meta-analyses of RCTs demonstrated that GLP-1 RAs improve cardiovascular outcomes [16–20] The American Diabetes Association (ADA) recommends SGLT-2 inhibitors or GLP-1 RAs in type 2 DM patients who have atherosclerotic cardiovascular disease or kidney disease [21]. This evidence concerns the gene GLP1R and kidney disorder.